Q-omics provides the consensus-scored GALR1 profile across patient tissues and cancer cell-line models. GALR1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GALR1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, GALR1 RNA expression shows 10,800 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, COAD, and TGCT as cancer lineages where GALR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALR1 survival associations across molecular data types. GALR1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALR1 RNA expression–survival associations across cancer types. High GALR1 expression shows unfavorable associations in UVM, UCEC, ACC and MESO, but favorable associations in KIRC and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GALR1 RNA expression.
This table summarizes GALR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for GALR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALR1 shows lower tumor expression in COAD, KIRP, BRCA, BLCA and STAD and higher tumor expression in KIRC. The COAD box plot shows higher GALR1 RNA expression in normal versus tumor tissue (log2 FC = −0.228, t-test p < 0.001).
This table shows molecular features associated with GALR1 in patient tissues and cancer cell lines. In patient samples, GALR1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GALR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
